A method for coating fucoidan onto bare metal stent and in vivo evaluation

[1]  P. Serruys,et al.  Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial , 2012, The Lancet.

[2]  Y. Hayashi,et al.  Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.

[3]  C. Terkelsen,et al.  Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.

[4]  P. Serruys,et al.  Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.

[5]  Haeshin Lee,et al.  Thromboresistant and endothelialization effects of dopamine-mediated heparin coating on a stent material surface , 2012, Journal of Materials Science: Materials in Medicine.

[6]  Daniel J. Kelly,et al.  The consequences of the mechanical environment of peripheral arteries for nitinol stenting , 2011, Medical & Biological Engineering & Computing.

[7]  D. Márton,et al.  Long-term stability of self-assembled monolayers on electropolished L605 cobalt chromium alloy for stent applications. , 2011, Journal of biomedical materials research. Part B, Applied biomaterials.

[8]  F. Alfonso,et al.  Paclitaxel-eluting balloons for sirolimus-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.

[9]  M. Jeong,et al.  Fabrication and controlled release of electrosprayed ReoPro-loaded metal surface for vascular stent , 2011 .

[10]  G. Stone,et al.  Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. , 2011, JACC. Cardiovascular interventions.

[11]  G. Mani,et al.  Paclitaxel delivery from cobalt-chromium alloy surfaces using self-assembled monolayers. , 2011, Biointerphases.

[12]  B. Buchholz,et al.  Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies. , 2011, Journal of pharmaceutical and biomedical analysis.

[13]  Karla S. Brammer,et al.  Plasma-induced nanopillars on bare metal coronary stent surface for enhanced endothelialization. , 2010, Acta biomaterialia.

[14]  Guixue Wang,et al.  Mesenchymal stem cell seeding promotes reendothelialization of the endovascular stent. , 2010, Journal of biomedical materials research. Part A.

[15]  M. Jeong,et al.  Preparation of a drug-eluting stent using a TiO2 film deposited by plasma enhanced chemical vapour deposition as a drug-combining matrix , 2010 .

[16]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[17]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[18]  R. Richard,et al.  Controlled delivery of paclitaxel from stent coatings using novel styrene maleic anhydride copolymer formulations. , 2009, Journal of biomedical materials research. Part A.

[19]  Li Shen,et al.  The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. , 2009, Biomaterials.

[20]  Bo Li,et al.  Fucoidan: Structure and Bioactivity , 2008, Molecules.

[21]  Shingo Nakamura,et al.  Effect of controlled release of fibroblast growth factor-2 from chitosan/fucoidan micro complex-hydrogel on in vitro and in vivo vascularization. , 2008, Journal of biomedical materials research. Part A.

[22]  A. Zurakowski,et al.  Prospective registry evaluating safety and efficacy of cobalt-chromium stent implantation in patients with de novo coronary lesions. , 2007, Kardiologia polska.

[23]  T. Konishi,et al.  Anti-proliferative activity of oversulfated fucoidan from commercially cultured Cladosiphon okamuranus TOKIDA in U937 cells. , 2007, International journal of biological macromolecules.

[24]  Maeve Kelly,et al.  A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. , 2007, Glycobiology.

[25]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[26]  A. Kastrati,et al.  Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. , 2007, Journal of the American College of Cardiology.

[27]  K. Kang,et al.  Bifunctional effects of fucoidan on the expression of inducible nitric oxide synthase. , 2006, Biochemical and biophysical research communications.

[28]  N. A. Scott,et al.  Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. , 2006, Advanced drug delivery reviews.

[29]  A. Kastrati,et al.  Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double‐blind controlled trial , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[30]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[31]  L. Gruberg,et al.  Late stent thrombosis after implantation of a sirolimus‐eluting stent , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[32]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[33]  T. Sugimura,et al.  Preventive Effects of Cladosiphon Fucoidan Against Helicobacter pylori Infection in Mongolian gerbils , 2003, Helicobacter.

[34]  S. Feng,et al.  Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[35]  E Regar,et al.  Stent development and local drug delivery. , 2001, British medical bulletin.

[36]  B. Abella,et al.  Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis , 2001, Circulation.

[37]  M. S. Williams,et al.  Stent and artery geometry determine intimal thickening independent of arterial injury. , 2000, Circulation.

[38]  Myung Ho Jeong,et al.  Preventive effects of the heparin‐coated stent on restenosis in the porcine model , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[39]  K. March,et al.  Gene therapy for restenosis: getting nearer the heart of the matter. , 1998, Circulation research.

[40]  D. Letourneur,et al.  Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization. , 1997, European journal of cell biology.

[41]  C L Seidel,et al.  Cellular heterogeneity of the vascular tunica media. Implications for vessel wall repair. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[42]  E. Edelman,et al.  Endovascular stent design dictates experimental restenosis and thrombosis. , 1995, Circulation.

[43]  R. Califf,et al.  Clinical trials of restenosis after coronary angioplasty. , 1991, Circulation.

[44]  R. Califf,et al.  Restenosis after coronary angioplasty: an overview. , 1991, Journal of the American College of Cardiology.

[45]  Clowes Aw,et al.  Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[46]  C. Blondin,et al.  Polysaccharides for vascular cell targeting. , 2000, Critical reviews in therapeutic drug carrier systems.